Is CaMKII equally responsible for inducing sarcoplasmic reticulum Ca2+ leak in human ischemic and dilated cardiomyopathy?
CaMKII inhibition may be a beneficial therapeutic strategy for the majority of heart failure patients, regardless of whether the etiology is ischemic or dilated cardiomyopathy.
Functional and molecular measures of the SR Ca(2+) leak are comparable in human ICM and DCM. CaMKII is equally responsible for the induction of the 'RyR2 leakiness' in both pathologies. Thus, CaMKII inhibition as a therapeutic measure may not be restricted to patients suffering from DCM but rather may be beneficial for the majority of HF patients.
Fischer et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: